CD274 and non-small cell lung carcinoma: Immunotherapy monotherapy (atezolizumab, pembrolizumab, or cemiplimab) is used as the first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥ 50% of TC [3–5].